Correlation of Wnt5a expression with histopathological grade/stage in urothelial carcinoma of the bladder by Ramiro Malgor et al.
Malgor et al. Diagnostic Pathology 2013, 8:139
http://www.diagnosticpathology.org/content/8/1/139RESEARCH Open AccessCorrelation of Wnt5a expression with
histopathological grade/stage in urothelial
carcinoma of the bladder
Ramiro Malgor1*, Seth Crouser1, Danielle Greco1, Colin Brockett1, Karen Coschigano1, Masato Nakazawa2
and Scott Jenkinson3Abstract
Background: Bladder cancer, including urothelial carcinoma (UC), is the most common malignancy of the urinary
tract and the fourth most frequent cancer overall in men. Wnt5a, a member of the Wnt family of proteins, has been
shown to have contradictory roles in the pathogenesis of many cancers, acting either as tumor suppressor or tumor
promoter. The objective of this study was to investigate the expression and role of Wnt5a in the pathogenesis of
UC and suggest possible clinical applications for diagnosis, prognosis and treatment.
Methods: We characterized the expression of Wnt5a in 33 human UC samples using immunohistochemistry. The
samples were obtained via transurethral resection, immediately fixed in formalin and then embedded in paraffin.
The correlation between Wnt5a immunoreactivity, histological grade, and pathological stage of the tumor was
analyzed. The expression of Wnt5a mRNA as well as the effect of Wnt5a on cell migration was also evaluated in
two UC cell lines, T24 and J82, and a normal urothelial cell line.
Results: Our immunohistochemical results revealed that Wnt5a staining intensity correlated positively with the
histological grade and pathological stage of the UC. Wnt5a mRNA expression differed widely in the three urothelial
cell lines, with high levels in one carcinoma cell line and low levels in the other cell line in comparison to the
normal urothelial cell line. Migration increased in both UC cell lines in response to Wnt5a treatment.
Conclusions: Our results show that the Wnt5a pathway may play a role in the pathogenesis of UC and suggest
that Wnt5a may serve as an additional, complementary diagnostic/prognostic marker for UC.
Virtual slide: http://www.diagnosticpathology.diagnomx.eu/vs/1952312091979566
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Urinary bladder cancer is the fourth most frequent can-
cer overall in men in developed countries [1] and the
most common malignancy of the urinary tract [2,3].
Worldwide, 297,338 new cases and 112,255 deaths due
to bladder cancer in males were reported in 2008 [3]. In
the United States, it is estimated that there will be
54,610 new cases of bladder cancer and 10,820 deaths in
2013 [4]. Approximately 95% of the tumors arising in the
bladder originate in the urothelium, resulting in urothelial* Correspondence: malgor@ohio.edu
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reproduction in any medium, provided the orcarcinoma (UC). Squamous cell carcinoma and adenocar-
cinoma are the other major forms of malignant tumors in
the bladder.
Two important biological features of UC are its re-
currence and its progression from superficial to invasive
tumors. Approximately 50-65% of patients with noninva-
sive UC develop a recurrent tumor within 5 years after
the first treatment [3]. A majority of tumors at pTa stage
are low grade and less than 5% of the tumors in this
group will progress to a higher stage. In contrast, most
of the tumors at pT1 pathological stage, which include
tumors with invasion into the lamina propria, are high
grade; 30-50% of the tumors in this group will progress
to a higher stage [1,2]. These features make UC challengingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment, or follow-up for each individual patient.
Wnt proteins are a group of secreted glycoproteins
that play critical physiological roles during embryonic
development, regulating cell proliferation, morphology,
motility and fate [5]. Aberrant Wnt signaling has been
implicated in pathological conditions such as cancer
and inflammatory diseases [6-10]. The canonical or β-
catenin dependent signaling pathway is well recognized
pathway in the Wnt family and is involved in normal
cell growth and differentiation as well as in cancer. In
the context of bladder cancers the hypermethylation of
Wnt antagonist genes such as Wnt inhibitory factor 1
(WIF1), mutations in adenomatous polyposis coli (APC)
and aberrant expression of β-catenin have been reported
to be associated with increased aggressiveness and poor
prognosis [11-15]. Recently, epigenetic deregulation of
Wnt pathway inhibitors has been implicated in abnor-
mal activation of the canonical Wnt signaling pathway
in bladder tumors [16]. All of these findings demon-
strated the probable role of the canonical Wnt signaling
pathway in the pathogenesis of UC of the bladder.
Wnt5a is a member of the Wnt family that belongs to a
non- canonical/non- transforming signaling pathway. The
non-canonical signaling involves numerous cellular path-
ways, all of them β-catenin-independent; however, based
on the specific Wnt receptors present, Wnt5a can inhibit
or promote β-catenin dependent signaling, which results
in contradictory roles of Wnt5a in cancer [17]. Wnt5a has
been described as a tumor promoter and a tumor sup-
pressor for different malignancies [6,17]. It has been im-
plicated in cancer progression as a potent enhancer of cell
motility and invasiveness for malignant melanoma [18].
Up-regulation of Wnt5a has been observed in lung, sto-
mach, colon, breast, pancreas and prostate cancer as well
[7,19,20]. The opposite function for Wnt5a, as a tumor
suppressor, has been described in hematopoietic, brain,
thyroid and colorectal cancers [21-23]. Specifically, Wnt5a
has been shown to act as a tumor suppressor for colorec-
tal carcinoma by antagonizing canonical Wnt/β-catenin
signaling [23].
The role of Wnt5a in the pathogenesis/progression of
UC has not been fully elucidated [14,15]. Olson et al.
reported the role of Wnt5a as a tumor suppressor gene in
UC because ectopic expression of human Wnt5a in a UC
cell line lacking the chromosomal region where Wnt5a re-
sides abolished the cell’s tumorigenic capacity [24]. Des-
pite efforts to clarify the role of the non-canonical Wnt
signaling pathway, and Wnt5a in particular, in the patho-
genesis of UC, much is still unknown.
The aim of this study was to investigate the expression
of Wnt5a protein in human UC. To accomplish this, we
examined the expression of Wnt5a by immunohisto-
chemistry (IHC) in 33 formalin-fixed, paraffin-embedded(FFPE) human UC samples. We found a significant posi-
tive correlation between Wnt5a expression and the
histological grade and pathological stage of the tumor.
Using in vitro methods, we also found that Wnt5a may
be involved in the migration of malignant UC cells,
which could have implications regarding the invasiveness
of the tumor.
Materials and methods
Human urothelial carcinoma tissue specimens
Samples from 33 patients collected at the time of diagnos-
tic/therapeutic transurethral resection and diagnosed as
urothelial carcinoma of the bladder were included in this
study. FFPE tissue blocks were archived at the University
Medical Associates - Pathology Department (UMA-Path-
ology lab, Athens, OH). Ethical approval for the study was
obtained from the Ohio University Institutional Review
Board (IRB 07E112).
The diagnosis and classification of the 33 samples were
performed according to the WHO/ISUP consensus classi-
fication system and the American College of Surgeon’s
Cancer Program Standards. Hematoxylin and eosin (H&E)
stains were used for diagnosis and staging of the tumors.
Pathological stage was determined by the degree of in-
vasion into the lamina propria. Histological grade was
defined based on architecture, polarity, thickness, and co-
hesiveness, as well as cytologic features including pleo-
morphism, chromasia, presence of nucleoli, mitosis and
umbrella cells.
Immunohistochemistry
FFPE tissue specimens were immunostained for Wnt5a
using a Wnt5a polyclonal antibody. For each case, two
consecutive 4 μm sections were mounted onto Superfrost
glass slides. Sections were deparaffinized followed by anti-
gen retrieval using 10 mM citrate buffer, pH 6.0, at 90°C
for 30 minutes. Endogenous peroxidase activity was
blocked with 3% H2O2 in phosphate buffered saline (PBS).
Endogenous biotin and avidin were blocked using the
Streptavidin/Biotin Blocking Kit (Vector Laboratories, Inc.,
Burlingame, CA). Rabbit polyclonal antibody against hu-
man Wnt5a (Santa Cruz Biotechnology, Santa Cruz, CA)
was applied to one of the two sections at 4 μg/ml diluted in
1% bovine serum albumin (BSA), in PBS. As an isotype
control, normal rabbit IgG (Invitrogen, Grand Island, NY)
was applied to the other section at the same concentration.
Slides were incubated overnight at 4°C in a humidified
chamber. A peroxidase-based visualization kit, Universal
LSAB™ +Kit/HRP, Rabbit/Mouse/Goat, was subsequently
used according to the manufacturer’s protocol (Dako North
America, Inc., Carpinteria, CA). Briefly, after three washes,
the slides were incubated with the biotinylated secondary
antibody for 20 minutes, washed three times, incubated
with streptavidin-HRP for 20 minutes, developed with 3,3′-
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MO) for 3 minutes, and counterstained with hematoxylin.
Wnt5a staining was scored as the intensity of staining in
tumor cells (ignoring staining in surrounding non-tumor
tissue) on a scale of 0 (no staining) to 3 (high intensity) by
two independent observers. Cases with discrepant scores
were re-evaluated jointly until agreement was reached.
Cell culture
HTB-1™ (J82) and HTB-4™ (T24) urothelial carcinoma
cell lines (ATCC, Manassas, VA) were cultured in Ea-
gle’s Minimum Essential Medium and McCoy’s 5a
Medium Modified, respectively, according to ATCC
recommendations. The T24 cell line, characterized as
non-tumorigenic, was derived from a poorly differenti-
ated, high histological grade, recurrent tumor. The J82
cell line, with tumorigenic capacity, was derived from a
poorly differentiated, high grade, invasive UC tumor
[25]. The normal urothelial cell (NUC) line (Lifeline Cell
Technology, Walkersville, MD) was cultured in ProstaLife™
Prostate Epithelial Cell Culture Medium according to
the manufacturer’s recommendations. Control conditioned
medium (cCM) was prepared using L cells (CRL-2648™,
ATCC) grown in ATCC-formulated Dulbecco’s Modified
Eagle’s medium plus 10% fetal bovine serum. Wnt5a-
conditioned medium (Wnt5aCM) was prepared using L
Wnt-5A cells (CRL-2814™, ATCC) grown in Dulbecco’s
Modified Eagle’s medium with 4 mM L-glutamine provided
by ATCC and supplemented with 0.6 mg/ml G418 and
10% fetal bovine serum. For each conditioned medium, the
cells were split 1:10 in culture medium (without G418) in
10 cm petri dishes and grown for 4 days. The medium was
subsequently removed and sterilized by filtration (first
batch of conditioned medium). Fresh culture medium
(without G418) was added and cultured for 3 more days.
The medium was removed again and sterilized as above
(second batch of conditioned medium). The first and sec-
ond batches were mixed 1:1 and kept frozen until needed.
Real time PCR
RNA was extracted from cells grown in 6-well plates using
the RNeasy® Mini kit (Qiagen, Valencia, CA) following the
manufacturer’s protocol. One microgram of RNA from
each sample was reverse transcribed to cDNA using the
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). Real-time quantitative PCR
was performed in duplicate for each sample using a gene-
specific Taqman probe, Taqman™ Gene Expression Master
Mix, and a StepOnePlus™ Real-Time PCR System according
to the manufacturer’s protocol (Applied Biosystems, Foster
City, CA). Wnt5a (Hs00180103_m1) and the following six
potential housekeeping genes were assayed: HPRT (Hs
99999909), GAPDH (Hs99999905), ACTB (Hs99999903),
B2M (Hs99999907), UBC (Hs00824723), and SDHA (Hs00188166). The most stable housekeeping genes were se-
lected for normalization purposes using the Normfinder al-
gorithm as outlined by Andersen et al. [26]. After
normalization, data were presented as the fold change of
Wnt5a RNA expression in each UC cell line relative to the
level of expression observed in the NUC cells.
Migration assay
Migration of T24 and J82 cells was qualitatively examined
by scratch assay and then quantified using the Oris™ Cell
Migration Assay kit (Platypus Technologies, LLC, Madi-
son, WI) according to the manufacturer’s protocol. For
the scratch assay, T24 and J82 cells were grown to conflu-
ence. The monolayers were washed with PBS, a cross was
scratched into the surface of each monolayer, and then the
cells were incubated with either regular medium (RM) in
which each cell line normally grew, or cCM or Wnt5aCM,
prepared as described above. Cellular migration was ob-
served and visually recorded at 24 h intervals.
For the Oris Cell Migration Assay, a 96-well plate was
populated with silicone stoppers and cells were added to
each well. When the cells were confluent, the stoppers were
removed and the clear area defined as the area before
migration. The cells were then incubated under four differ-
ent conditions: RM, RM supplemented with recombinant
Wnt5a (R&D Systems) at 100 ng/ml (rWnt5a), cCM or
Wnt5aCM. The cells were allowed to grow for 24 hours
and then migration was stopped by fixation with 10% for-
malin. Each well was digitally imaged and traced, with the
migration area defined as the percentage of the previously
clear area now occupied by cells after 24 hours of growth.
The measurements were performed using Image-Pro® Plus
(Media Cybernetics, Inc., Silver Spring, MD).
Statistical analysis
Logistic regression statistical analysis was performed to in-
vestigate the correlation between Wnt5a immunostaining
and two variables, tumor histological grade and patho-
logical stage. Cell migration was evaluated using t-tests to
compare the effect of different treatments versus control.
Statistical significance was tested at an alpha of 0.05. The
software SPSS version 17 was used for data analysis (IBM
SPSS, Armonk, NY).
Results
Wnt5a immunostaining increases with increasing
histological grade and pathological stage of the tumor
Histological grade and pathological stage were determined
in all 33 samples of human UC included in the study. The
samples were diagnosed as noninvasive papillary UC of low
grade (12 samples), noninvasive papillary UC of high grade
(8 samples) or invasive UC (13 samples, all high grade). For
pathological stage of the disease, 20 of 33 cases were in








Figure 1 Wnt5a expression in three cases of low grade, noninvasive, papillary urothelial carcinoma as assessed by IHC. (A) H&E staining;









Figure 2 Wnt5a expression in three cases of high grade urothelial carcinoma as assessed by IHC. (Top row) Noninvasive urothelial
carcinoma (pTa stage); (middle row) a case with lamina propria invasion (pT1 stage); (bottom row) a case with muscle invasion (pT2 stage); (A)
H&E staining; (B) Wnt5a immuno-staining showing strong reactivity; (C), isotype control (all at × 200).














Figure 3 Wnt5a expression in three cases of high grade, invasive urothelial neoplasms (pT2 stage) as assessed by IHC. (A) H&E staining
at low magnification shows deep invasion areas in the bladder wall (×40); (B) H&E staining (×200); (C) Wnt5a immune-staining showing strong
reactivity (×200); (D) isotype control (×200).
Table 2 Correlation of Wnt5a staining intensity and
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confined to, tumor cells in all 33 samples (Figures 1, 2 and
3). Specificity of Wnt5a staining was demonstrated by the
lack of staining in the isotype controls. Intensity of Wnt5a
staining positively correlated with the histological grade of
the tumor (Table 1). Of the 12 samples classified as nonin-
vasive papillary UC of low grade, six samples (50%) were 1+
for Wnt5a staining, four samples (33%) were 2+, and
only two samples (17%) were 3+. In contrast, of the 21
samples classified as high grade, including noninvasive
and invasive UC, 20 cases (95%) were 2+ or 3+ and only
one case (5%) was scored as 1+. Staining intensity pre-
dicted a binary dependent variable of tumor grade (odds
ratio = 1.29 [IC95: 1.03 ~ 1.60], p = 0.033); an increase in
staining intensity was associated with an increased odds
ratio (OR) of 1.29. This effect of staining intensity was not
moderated by the stage (interaction between intensity and
stage, p = 0.14), indicating that intensity predicted the
tumor grade regardless of the stage. In fact, the staining
intensity predicted the tumor grade at every stage (OR at
stages 1–3 = 1.43, 2.00, 1.70; ps < 0.01).Table 1 Correlation of Wnt5a staining intensity and










* 1+ weak; 2+ moderate; 3+ strong.Intensity of Wnt5a staining also positively correlated
with the pathological stage of the tumor (Table 2). Of
the cases with noninvasive disease (stage pTa), seven of
20 (35%) had a low score 1+; eight of 20 (40%) were 2+
and five of 20 (25%) scored 3+ for Wnt5a immo-
nostaining. In contrast, of seven UC samples that had
invasion into the lamina propria (stage pT1), five (71%)
were 2+ and the remaining two (29%) were 3+. Further,
of the five samples with invasion into detrusor muscle
(stage pT2), one (20%) had a score of 2+ while the
remaining four (80%) had a score of 3+. Statistical ana-
lysis showed that staining intensity predicts the tumor
stage; the OR for the staining intensity effect was sig-
nificant (OR = 4.37, p = 0.017). In other words, for one












^ pTa: non invasive; pT1: invasion to the lamina propria; pT2: invasion of the
detrusor muscle; N.D.: could not be determined.
* 1+ weak; 2+ moderate; 3+ strong.








6 (1+) 1 (1+)
4 (2+) 4 (2+)









N.D. 1 ——— 1 (3+)
^ pTa: non-invasive; pT1: invasion to the lamina propria; pT2: invasion of the
detrusor muscle; N.D.: could not be determined.
* 1+ weak; 2+ moderate; 3+ strong.
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4.37 [95% CI: 1.43-16.74].
Finally, correlation of stage, grade and Wnt5a staining of
the UC samples was also assessed (Table 3). Not sur-
prisingly, all 12 tumors showing invasive properties (pT1
or pT2) were also high grade and exhibited moderate to
strong (2+ or 3+) Wnt5a staining. Interestingly, of the
eight high grade, noninvasive tumors, only one (12.5%)Figure 4 Wnt5a mRNA expression in a normal urothelial cell line (NU
assessed by real time RT/PCR. The average fold change ± standard error
normalization with two different housekeeping genes, SDHA (left) and B2Mhad weak (1+) staining while seven (87.5%) had moderate
to strong (2+ or 3+) Wnt5a staining.Wnt5a mRNA expression differs widely between
urothelial cell lines
Wnt5a mRNA expression was compared among three
cells lines: a normal urothelial cell line (NUC) and two
different urothelial carcinoma cell lines (J82 and T24).
Interestingly, in comparison to the normal urothelial
cell line, Wnt5a mRNA expression was increased more
than 3-fold in the J82 cell line but decreased 10-fold in
the T24 cell line (Figure 4).Exogenously applied Wnt5a results in different migration
rates of UC cell lines
Scratch assays showed that application of Wnt5a in
the medium appears to increase the migration rates for
both J82 and T24 UC cell lines, with more dramatic
results for the faster growing T24 cell line (Figure 5).
To validate and quantify these results, we repeated the
experiment using an Oris Cell Migration Assay kit
(Figure 6). In comparison to regular and control-
conditioned media, application of Wnt5a-conditioned
medium significantly increased migration of T24 cells.
Addition of recombinant Wnt5a instead of conditioned
medium had little effect on T24 migration. In contrast,C) and two urothelial carcinoma cell lines, J82 and T24, as
(SE) for each cell line is shown in comparison to NUC after
(right).
RM               cCM Wnt5aCM
Figure 5 Application of Wnt5a-conditioned medium increases migration of T24 and J82 cell lines in scratch assays. Scratch assays are
shown at time 0 (0 hours) and then 24 hours (T24) or 48 hours (J82) after the application of three different treatments: regular growth medium






































RM         rWnt5a        cCM Wnt5aCM 
Figure 6 Differing migration rates for T24 and J82 cell lines in
response to exogenous Wnt5a. Average migration area ± SE was
determined using the Oris Cell Migration Assay kit 24 hr after
application of regular medium (RM), regular medium supplemented
with recombinant Wnt5a at 100 ng/ml (rWnt5a), control-conditioned
medium (cCM), or Wnt5a-conditioned medium (Wnt5aCM). (A)
Migration rate for the T24 cell line; (B) migration rate for the J82 cell
line. * p = 0.05; ** p = 0.022.
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migration rate for J82 cells, although the difference did
not reach statistical significance. Addition of Wnt5a-con
ditioned medium had no significant effect.
Discussion
Urinary bladder cancer is the fourth most frequent cancer
in men in the world today [1-3]. Due to its great plasticity
and biological variability with respect to multifocality,
recurrence, and invasion comportment, it is difficult to
predict the behavior of an initially noninvasive UC [2,3].
This feature makes the diagnosis of UC challenging, not
only for its early detection, but also for accurate prediction
of tumor recurrence and progression.
Multiple biomarkers used for other cancers have been
described with potential diagnostic or prognostic value for
UC as well, including p53, cytokeratin 20, E-cadherin,
Ki67, CD44 and survivin [27,28]. Currently a combination
of these immunohistochemical biomarkers assayed within
panel is the best way to characterize subtypes and predict
the behavior/aggresiveness of UC [28]. More recently,
other promising biomarkers for UC have been reported.
In a large retrospective exploratory study, expression of
microRNA-100 was negatively associated with stage, re-
currence, prognosis and death of patients with bladder
cancer [29]. In another large study, the cell surface zinc-
dependent metalloprotease CD10 was strongly correlated
with tumor grade and stage and possibly associated with
tumor progression in bladder cancer pathogenesis [30]. In
contrast to initial studies correlating increased COX-2 ex-
pression and recurrence of urinary bladder cancer, a large
study focused on non-muscle invasive bladder cancer
found that lower levels of COX-2 and tumor-infiltrating
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need of close follow-up and adjuvant therapy for these
patients [31]. In the current study Wnt5a protein expres-
sion by malignant cells was observed in all 33 samples in-
cluded in the study; however, intensities, and hence
protein levels, varied, correlating with both grade and
stage and suggesting that Wnt5a may also serve as a
biomarker of UC. To prove the predictive nature of
Wnt5a as a diagnostic or prognostic biomarker of UC,
further investigation into the relationship between Wnt5a
expression by the tumor and clinical progression of the
disease in a large number of patients, is required.
Expression of Wnt5a by UC tumor cells may also be a
predictor of an aggressive subgroup of UC. We found
that weak Wnt5a expression was predominantly seen in
low grade UC samples and all were in a noninvasive
(pTa) stage. This suggests that low Wnt5a expression
may be indicative of non-aggressive tumors. In contrast,
moderate to strong Wnt5a expression was seen in all
three pathological stages, but was usually associated with
high grade, high stage tumors. Thus, moderate to strong
expression of Wnt5a is likely to indicate an aggressive
tumor or transformation to an invasive phenotype. In
support of this hypothesis previous studies have reported
the role of Wnt5a as a pro-angiogenic gene [32,33] and
also the importance of the Wnt signaling pathway in
epithelial-mesenchymal transition (EMT) of cancer [34].
In addition, Huang CL et al. reported the association of
Wnt5a with tumor proliferation in non-small-cell lung
cancer (NSCLC); the authors concluded that over-
expression of Wnt5a could increase aggressiveness in
NSCLC [35].
The present study also assessed Wnt5a mRNA expres-
sion in two UC cell lines, both from high grade, poorly dif-
ferentiated tumors. Interestingly, the expression differed
significantly between them, with one of the cancer cell
lines expressing much higher levels and the other express-
ing much lower levels of Wnt5a mRNA in comparison to
the normal urothelial cell line. This result is similar to the
result published many years ago by Bui et al. in which they
described different Wnt5a mRNA expression levels for
different UC cell lines [36]. In that study the authors
suggested that Wnt5a may modulate cell shape and cell
migration [36].
In support of a role of Wnt5a in cell migration, Wnt5a
has been associated with migration ability in melanoma
[18]. Our group previously reported constitutive Wnt5a
expression in human pancreatic cancer and malignant
melanoma cell lines and suggested the role of Wnt5a in
growth and migration in both of these cancer cell lines
[19]. In this study we investigated migration response to
exogenously applied Wnt5a in the two UC cell lines. We
found that the T24 cell line, which has a low level of
Wnt5a transcription, showed a significant increase inmigration rate while J82, with high Wnt5a transcription,
did not significantly respond to the application of
Wnt5a. It is possible that J82, with high Wnt5a RNA, is
already maximally saturated by Wnt5a and cannot re-
spond further, while T24, with low Wnt5a RNA, is sub-
maximally saturated and thus capable of responding to
exogenous Wnt5a. Alternatively, it is possible that different
cell lines have different responses to Wnt5a due to expres-
sion of different Wnt5a receptors. It is well known that
the interaction between Wnt ligands and their receptors
determine the signaling that will be activated, and multiple
receptors may respond to Wnt5a signaling, each leading
to activation of different downstream signaling pathways
and effects [17,37,38]. Therefore, different responses might
be associated with the presence of different receptors for
Wnt5a ligand in each tumor cell line.
Conclusion
In conclusion, our results support previous work sug-
gesting that the Wnt5a signaling pathway plays a patho-
logical role in UC. The correlation of Wnt5a protein
expression in UC tissue sections with histological grade
and pathological stage of the tumor suggests its possible
use as diagnostic/prognostic tool for UC. Further studies
to investigate association between Wnt5a expression,
tumor behavior and clinical outcome are necessary to fully
validate the utility of Wnt5a for early diagnosis/prognosis
of UC. Further studies are also needed to clarify the
underlying mechanisms connecting Wnt5a and different
tumor behavior. These investigations promise to deliver
predictability for a relatively unpredictable cancer.
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